Hong Kong's Hospital Authority has begun subsidizing the leukemia drug Dasatinib, significantly reducing patient costs from up to HK$500,000 annually to just HK$240 per year. This change, effective since April, reclassifies the drug from self-financed to a special drug, making it accessible to over 400 cancer patients. The government anticipates an additional HK$49 million in annual spending to cover these subsidies, alongside relaxed criteria for other drug subsidy funds. AI
RANK_REASON This is a significant policy change regarding drug subsidies and healthcare access in Hong Kong. [lever_c_demoted from significant: ic=1 ai=0.0]
AI-generated summary · Google Gemini · from 1 sources. How we write summaries →
